NCT07214740

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

A Phase 3B, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety of Pegcetacoplan in a Prefilled Syringe in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Apellis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)

Conditions

• Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	APL-2, Pegcetacoplan	Complement (C3) Inhibitor

Timeline

• Start date: 2025-10-24
• Primary completion: 2025-12-12
• Completion: 2025-12-12
• First posted: 2025-10-09
• Last updated: 2025-12-17

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study